Holen Sie sich die Stockscreener-App
29.35
1.71%
-0.51
Handel nachbörslich:
29.35
Neurogene Inc Aktie (NGNE) Neueste Nachrichten
This $20 Biotech Stock Just Got An FDA Boost – And A $200 Price Target - Stocktwits
Neurogene Inc. (NGNE) Holds Steady Near Resistance as Biotech Sector WatchesBreakaway Gap - newsline.com
Neurogene Inc. (NGNE) Q1 2026 Earnings: EPS Miss as Pre-Revenue Biotech Continues R&D InvestmentEPS Surprise History - newsline.com
NGNE Reiterated by HC Wainwright & Co. -- Price Target Maintained at $70 - GuruFocus
Neurogene stock rating reiterated at Buy by H.C. Wainwright - Investing.com South Africa
NGNE Q1 2026 Earnings: EPS Misses Estimates as Clinical Progress ContinuesGAAP Earnings Report - newsline.com
Neurogene (NGNE) Completes Dosing in Key Trial for NGN-401 - GuruFocus
Number of shareholders of Neurogene Inc. – NASDAQ:NGNE - TradingView
Neurogene Completes Dosing in Pivotal Embolden™ Trial of NGN-401 Gene Therapy for Rett Syndrome - Minichart
Neurogene Completes Dosing in Embolden Rett Trial - TipRanks
Neurogene completes dosing in Rett syndrome gene therapy trial By Investing.com - Investing.com Nigeria
Neurogene completes dosing in Embolden trial, doses 25 participants; topline data due 2H 2027 - TradingView
Neurogene Inc. finalizes administration phase in pivotal Embolden study - Traders Union
Neurogene completes dosing in Rett syndrome gene therapy trial - Investing.com
Neurogene (NGNE) finishes dosing in NGN-401 Embolden Rett registrational trial - Stock Titan
Neurogene Announces Successful Completion of Dosing in Embolden™ Registrational Trial of NGN-401 for Rett Syndrome - The Joplin Globe
25 girls receive Neurogene’s one-time gene therapy in key Rett syndrome trial - Stock Titan
Neurogene Inc. Files Form 8-K with SEC Detailing Corporate Information and NASDAQ Listing - Minichart
Neurogene Stockholders Vote on Directors and Executive Pay - TipRanks
Neurogene (NGNE) investors back board slate, pay plan and auditor - Stock Titan
NGNE Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Rodman & Renshaw initiates Neurogene stock with buy on gene therapy - Investing.com Nigeria
Two new Neurogene hires get options on 17,045 company shares - Stock Titan
Neurogene Inc. (NGNE) Gains 3% as Biotech Sentiment Lifts SharesETF Outflow Streak - newsline.com
William Blair Maintains Neurogene(NGNE.US) With Buy Rating - Moomoo
Analysts Offer Insights on Healthcare Companies: Alpha Tau Medical Ltd (DRTS), Neurogene (NGNE) and Milestone Pharmaceuticals (MIST) - The Globe and Mail
Neurogene’s Stock Run Is Riding A Rett Gene Therapy Bet - Finimize
NGNE Stock Chart | NEUROGENE INC (NASDAQ:NGNE) - ChartMill
Neurogene Inc. (NGNE) Shows Resilience: Gains 2.45% as Biotech Sector Looks to ReboundCrowd Entry Signals - newser.com
Neurogene Trades Around $27 With Street Watching Rett Data Test Midyear - Bez Kabli
Neurogene (NGNE) Q1 2026 Results Miss Estimates — EPS $-1.39 vs $-1.32Slow Growth Warning - Newser
NGNE News | NEUROGENE INC (NASDAQ:NGNE) - ChartMill
H.C. Wainwright Maintains Neurogene(NGNE.US) With Buy Rating, Maintains Target Price $70 - Moomoo
LifeSci Capital Sticks to Its Buy Rating for Neurogene (NGNE) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: RenovoRx (RNXT), Neurogene (NGNE) and ARS Pharmaceuticals (SPRY) - The Globe and Mail
LifeSci Capital Maintains Neurogene(NGNE.US) With Buy Rating, Maintains Target Price $60 - Moomoo
Neurogene (NGNE) Stock: Down -4.22%, Support Test at $28.45 2026-05-15Turnaround Stocks - Newser
Craig-Hallum Maintains Neurogene(NGNE.US) With Buy Rating, Announces Target Price $65 - Moomoo
Analysts Are Bullish on Top Healthcare Stocks: Acurx Pharmaceuticals (ACXP), Neurogene (NGNE) - The Globe and Mail
Neurogene (NGNE) Price Target Increased by 11.85% to 60.18 - MSN
Neurogene Inc. Stock 12‑Month Price Target Raised to $77.86, Implies 147% Upside - TradingView
Neurogene 1Q Loss $30.9M >NGNE - Moomoo
Neurogene : Corporate Presentation May 2026 - marketscreener.com
Neurogene: Q1 Earnings Snapshot - marketscreener.com
Neurogene Q1 net loss widens on higher R&D costs - TradingView
Rett gene therapy trial nears full dosing, no HLH cases at 1E15 vg - Stock Titan
Rett gene therapy progress highlights Neurogene (NGNE) Q1 2026 update - Stock Titan
Neurogene Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Neurogene (NGNE) boosts Rett R&D as Q1 2026 net loss deepens - Stock Titan
Neurogene Inc. unveils new data on ICV gene therapy approach at ASGCT2026 - Traders Union
Neurogene Highlights Data at ASGCT Meeting Supporting Therapeutic Rationale for ICV Delivery Method in CNS-targeted Gene Therapy - The Norfolk Daily News
Rett gene therapy trial reports 35 milestones after ICV brain procedure - Stock Titan
Neurogene Inc. president and CFO sells $300,043 in stock By Investing.com - Investing.com South Africa
Neurogene Inc. president and CFO sells $300,043 in stock - Investing.com India
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):